A Comparative Clinical Study on the Role of Mustak Vaca Haridra Kashaya and Pathya Churna as Nitya Virecak in the Management of Meda Dusti w.s.r to Dyslipidemia
DOI:
https://doi.org/10.47070/ijapr.v14i10.4440Keywords:
Dyslipidemia, Meda dusti, Mustak, Vaca, Haridra, Pathya, Lipid Profile, Meda rogaAbstract
In today’s fast-paced world dyslipidemia is a major lifestyle disorder, however there is no such phrase dyslipidemia in Ayurvedic texts but it can be clinically correlated with Meda dusti. Meda dhatu takes the initiative in this Dhatu pradosaja vikar which involves vitiation of Kapha Dosa along with Meda dhatu, and accumulation of Ama. Objectives To normalize serum lipid value using the trial drug Mustak Vaca Haridra Kashaya itself and the same introduced with Pathya Churna as Nitya virecak in the management of Meda dusti (dyslipidemia) comparatively and to find the effectiveness between both treatment protocols under coverage of prescribed Pathya and Apathya. Methods An open labelled comparative randomized controlled clinical trial was done among 60 patients subjected to be suffering from Meda Dusti (dyslipidemia) or a known case of it, visiting the OPD of I.P.G.A.E & R at SVSP, Kolkata. The patients were divided into two groups. Group A received Mustak Vaca Haridra Kashaya and Group B received Mustak Vaca Haridra Kashaya with Pathya Churna as Nitya virecak for a duration of 45 days. Assessment was carried out using serum lipid profile and subjective parameters, BMI and safety laboratory investigations. Results Both the groups showed statistically significant results. The combined drug used in this trial i.e., Mustak Vaca Haridra Kashaya introduced with Pathya churna as nitya virecak has pronounced effect than Mustak Vaca Haridra Kashaya alone itself over Meda dusti (dyslipidemia). No systemic adverse effect was found during the entire clinical trial.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Ayurveda and Pharma Research

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

